Kentaro Mitsui

Kentaro Mitsui

Auto-generated profile, based on publicly available information

Kentaro Mitsui

Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2023 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Open access
KMKentaro Mitsui
Kentaro Mitsui
TLTETSUMIN LEE
TETSUMIN LEE
RMRyoichi Miyazaki
Ryoichi Miyazaki
NHNobuhiro Hara
Nobuhiro Hara
SNSho Nagamine
Sho Nagamine
TATakashi Ashikaga
Takashi Ashikaga
Background: Percutaneous coronary intervention (PCI) for calcified coronary artery remains challenging in the drug‐eluting stent (DES) era. While recent studies reported the efficacy of orbital atherectomy (OA) combined with DES for calcified lesion, the effectiveness of drug‐coated balloon (DCB) following OA has not been fully elucidated.Methods: Between June 2018 and June 2021, 135 patients who received PCI for calcified de novo coronary lesions with OA were enrolled and divided into two groups; OA followed by DCB (n = 43) if the target lesion achieved acceptable preparation, or second‐ or third‐generation DESs (n = 92) if the target lesion showed suboptimal preparation between June 2018 and June 2021. All patients underwent PCI with optical coherence tomography (OCT) imaging. The primary endpoint was 1‐year major adverse cardiac event (MACE), that was a composite of cardiac death, nonfatal myocardial infarction, or target lesion revascularization.Results: Mean age was 73 years and 82% was male. In OCT analysis, maximum calcium plaque was thicker (median: 1050 µm [interquartile range (IQR): 945–1175 µm] vs. 960 µm [808–1100 µm], p = 0.017), calcification arc tended to larger (median: 265° [IQR: 209–360°] vs. 222° [162–305°], p = 0.058) in patients with DCB than in DES, and the postprocedure minimum lumen area was smaller in DCB compared with minimum stent area in DES (median: 3.83 mm2 [IQR: 3.30–4.52 mm2] vs. 4.86 mm2 [4.05–5.82 mm2], p < 0.001). However, 1 year MACE free rate was not significantly different between 2 groups (90.3% in DCB vs. 96.6% in DES, log‐rank p = 0.136). In the subgroup analysis of 14 patients who underwent follow‐up OCT imaging, late lumen area loss was lower in patients with DCB than DES, despite lower lesion expansion rate in DCB than DES.Conclusions: In calcified coronary artery disease, DCB alone strategy (if acceptable lesion preparation was performed with OA) was feasible compared with DES following OA with respect to 1‐year clinical outcomes. Our finding indicated using DCB with OA might be reduce late lumen area loss for severe calcified lesion.

25 May 2022 in Circulation Journal
Verified
Journal Article
Open access
PDF file
NHNobuhiro Hara
Nobuhiro Hara
TLTETSUMIN LEE
TETSUMIN LEE
TNToshihiro Nozato
Toshihiro Nozato
MMMao Terui Matsuyama
Mao Terui Matsuyama
SOShinichiro Okata
Shinichiro Okata
TATakashi Ashikaga
Takashi Ashikaga
Background:The efficacy of direct oral anticoagulants (DOACs) compared with warfarin for the treatment of venous thromboembolism (VTE), and the recurrence of VTE after discontinuation of anticoagulation therapy in research are limited. Methods and Results:This retrospective study enrolled 893 patients with acute VTE between 2011 and 2019. The cohort was divided into the transient risk, unprovoked, continued cancer treatment, and cancer remission groups. The following were compared between DOACs and warfarin: composite outcome of all-cause death, VTE recurrence, bleeding and composite outcome of VTE-related death, recurrence and bleeding. In the continued cancer treatment group, more bleeding was seen in warfarin-treated patients than in patients treated with DOACs (53.2% vs. 31.2%, [P=0.048]). In addition, composite outcome of VTE-related death and recurrence after discontinuation of anticoagulation therapy (n=369) was evaluated. The continued cancer treatment group (multivariate analysis: HR: 3.62, 95% CI: 1.84–7.12, P<0.005) and bleeding-related discontinuation of therapy (HR: 2.60, 95% CI: 1.32–5.13, P=0.006) were independent predictors of the event after discontinuation of anticoagulation therapy. VTE recurrence after discontinuation of anticoagulation therapy in the cancer remission group was 1.6% and a statistically similar occurrence was found in the transient risk group (12.4%) (P=0.754). Conclusions:DOACs may decrease bleeding incidence in patients continuing to receive cancer treatment. In patients with bleeding-related discontinuation of anticoagulation therapy, VTE recurrence may increase. Discontinuation of anticoagulant therapy might be a treatment option in patients who have completed their cancer treatment.

1 April 2026 in Circulation: Cardiovascular Interventions
Verified
Journal Article
Open access
NYNaoya Yabumoto
Naoya Yabumoto
MFMasashi Fujino
Masashi Fujino
EKEri Kiyoshige
Eri Kiyoshige
HSHiroki Sugane
Hiroki Sugane
HHHayato Hosoda
Hayato Hosoda
YKYu Kataoka
Yu Kataoka
BACKGROUND: Calcified nodules (CNs) represent a high-risk coronary lesion phenotype associated with target lesion revascularization (TLR). Although rotational atherectomy (RA) is an established treatment for calcified lesions, its benefit for CNs remains unclear. This study aimed to evaluate the impact of RA on TLR and to identify specific morphological features on intravascular ultrasound that may influence its therapeutic effect for CNs. METHODS: In a substudy of the U-SCAN registry (Coronary Intravascular Ultrasound for Calcified Nodule), 348 patients with CNs identified by intravascular ultrasound who underwent percutaneous coronary intervention were analyzed. We excluded patients with in-stent restenosis, use of alternative debulking devices, failed device passage without RA, and poor image quality. The final analysis included 209 patients, stratified by RA use. Multivariable Cox proportional hazards models were used to identify predictors of TLR and assess treatment interactions across subgroups. RESULTS: Among 209 patients, 79 patients (37.8%) underwent RA. During a median follow-up of 2.1 years (interquartile range, 0.4–4.9), TLR was required in 20 of 79 patients (25.3%) in the RA group and 41 of 130 patients (31.5%) in the non-RA group. After adjustment, RA independently predicted reduced TLR (hazard ratio, 0.34 [95% CI, 0.19–0.62], P <0.001). In addition, intravascular ultrasound–derived calcification features, including greater lumen area stenosis, longer CN length, smaller final minimum lumen area, and adjacent circumferential calcification, were significantly associated with TLR. Notably, the benefit of RA on TLR was pronounced in patients with contralateral calcification (8.6% versus 51.6%, P <0.001). In contrast, without this feature, the TLR rate was higher in the RA group (38.6% versus 25.3%, P =0.11), resulting in a statistically significant interaction ( P interaction <0.001). CONCLUSIONS: In patients with CNs, RA was associated with a reduced long-term risk of TLR. The presence of contralateral calcification identifies a subgroup deriving substantial benefit, supporting a more selective, morphology-guided approach to treatment. REGISTRATION: URL: https://jrct.mhlw.go.jp/ ; Unique identifier: jRCT1050240037.

12 January 2026 in Atherosclerosis
Verified
Journal Article
Open access
KMKentaro Mitsui
Kentaro Mitsui
YKYu Kataoka
Yu Kataoka
SNStephen J. Nicholls
Stephen J. Nicholls
EKEri Kiyoshige
Eri Kiyoshige
KNKunihiro Nishimura
Kunihiro Nishimura
TNTeruo Noguchi
Teruo Noguchi
Calcified plaques have traditionally been regarded as advanced and quiescent atheroma. However, pathological studies indicate lipid content within calcified plaques, suggesting that calcified plaques may harbor active lipidic contents. This study evaluated lipidic plaque content in calcified lesions in vivo using IVUS, OCT and near-infrared spectroscopy (NIRS). We analyzed 325 cross-sectional frames at 65 calcified lesions in 58 CAD patients from the REASSURE-NIRS registry (NCT04864171). OCT-derived calcification measures, and the arc of NIRS-derived yellow signals within calcification (YSC) were measured. Plaque features were compared between cross-sectional frames with YSC arc < and ≥63° (=median). The median calcification arc was 224° (statin = 78 %, LDL-C = 81.5 mg/dL), and 73.8 % of images exhibited calcification arc ≥180°. Any YSC was observed at 84.3 % of analyzed frames. YSC arc ≥63° was associated with thinner (743 ± 276 vs. 882 ± 247 μm, p < 0.001) and deeper calcification (median:50 vs. 30 μm, p = 0.002), whereas the frequency of macrophage (16.6 % vs. 11.7 %, p = 0.265), microvessels (0.6 % vs. 0.6 %, p = 1.000) and cholesterol crystals (1.2 % vs. 0.0 %, p = 0.498) did not differ between two groups. Multivariate analysis identified calcification thickness (β = -0.446, 95 % CI = -0.661-0.231, p < 0.001) as an independent predictor of YSC arc ≥63°, whereas calcification arc (β = 0.000, 95 % CI = -0.001-0.001, p = 0.788) and depth (β = -0.592, 95 % CI = -1.408-0.224, p = 0.155) were not. Notably, LDL-C<55 mg/dL was associated with larger calcification arc (p < 0.001), but the YSC arc was not necessarily smaller despite achieving LDL-C<55 mg/dL (p = 0.671). Lipidic contents existed at calcified lesions exhibiting thinner calcification. This lipidic feature at calcified lesions less likely undergo changes in response to LDL-C<55 mg/dL.

1 October 2021 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
KMKentaro Mitsui
Kentaro Mitsui
RORentaro Oda
Rentaro Oda
TLTETSUMIN LEE
TETSUMIN LEE
KWKeita Watanabe
Keita Watanabe
TNTomofumi Nakamura
Tomofumi Nakamura
TATakashi Ashikaga
Takashi Ashikaga

17 July 2026 in JACC: Asia
Verified
Journal Article
Open access
YKYu Kataoka
Yu Kataoka
SNStephen J. Nicholls
Stephen J. Nicholls
KRKausik K. Ray
Kausik K. Ray
AKAya Katasako-Yabumoto
Aya Katasako-Yabumoto
SKSatoshi Kitahara
Satoshi Kitahara
TNTeruo Noguchi
Teruo Noguchi